Can escitalopram (Lexapro) cause urinary retention or other bladder symptoms, and how should these be managed?

Escitalopram (Lexapro) and Bladder Effects

Escitalopram can cause urinary retention, particularly in elderly men with benign prostatic hyperplasia (BPH), and should be used with extreme caution or avoided in patients with known or latent urinary outflow obstruction.

Risk Profile and Mechanism

Escitalopram, while generally having a lower anticholinergic burden than tricyclic antidepressants, can still precipitate bladder dysfunction through multiple mechanisms:

• Direct detrusor inhibition: Laboratory studies demonstrate that escitalopram blocks L-type calcium channels in bladder smooth muscle, directly impairing detrusor contractility 1
• Urinary retention incidence: Among SSRIs, urinary retention occurs in approximately 0.025% of patients, though this is significantly lower than tricyclic antidepressants (17.6% for imipramine) 2
• Comparative safety: Escitalopram appears safer than duloxetine (an SNRI) for urinary flow parameters in elderly men 3

High-Risk Populations

Elderly men with BPH represent the highest-risk group. Multiple case reports document acute urinary retention (AUR) developing after initiating standard-dose escitalopram in men with previously diagnosed or latent/asymptomatic BPH 4. In these cases:

• Urinary retention resolved after escitalopram discontinuation in most patients
• One case required emergent prostatectomy
• Retention persisted even after stopping other potentially causative medications (e.g., ipratropium) until escitalopram was discontinued 5

The FDA label does not specifically list urinary retention as a contraindication but notes that escitalopram should be used with caution in patients with concomitant systemic illnesses 6.

Clinical Management Algorithm

For patients already on escitalopram with new bladder symptoms:

1. Immediately assess for urinary retention: Check post-void residual (PVR) volume
2. Rule out other causes: Exclude UTI, neurological conditions, and review all medications (anticholinergics, antihistamines, alpha-agonists)
3. If retention is present and other causes excluded: Discontinue or reduce escitalopram dose
4. Monitor closely: Symptoms typically resolve within days of discontinuation 4, 5
5. Consider alternative antidepressant: Switch to an SSRI with less bladder effect if depression treatment must continue

Before initiating escitalopram in at-risk patients:

• Screen for BPH symptoms: Use validated questionnaires (e.g., IPSS score)
• In elderly men (>55 years) with any voiding symptoms: Consider alternative antidepressants or proceed with heightened monitoring
• Baseline PVR measurement: Obtain in men with known BPH or lower urinary tract symptoms
• Patient counseling: Warn about urinary retention risk and instruct to report difficulty urinating immediately

Important Caveats

The evidence presents an apparent paradox: While case reports and mechanistic studies show escitalopram can cause urinary retention 4, 5, 1, one recent animal study suggests escitalopram may actually improve overactive bladder symptoms in a depression model 7. This likely reflects different mechanisms—direct bladder muscle effects versus central serotonergic modulation of bladder control.

In clinical practice, the retention risk predominates, particularly in:

• Men with anatomical bladder outlet obstruction (BPH)
• Patients with marginal urinary flow at baseline
• Elderly patients with multiple risk factors

A large pharmacovigilance study found that while escitalopram was associated with urinary retention signals, the effect was less pronounced than with SNRIs like duloxetine or tricyclic antidepressants 8. Among antidepressants, SSRIs cause primarily voiding dysfunction rather than storage symptoms 9.

Practical Recommendations

Do not prescribe escitalopram to men with:

• Known symptomatic BPH with elevated PVR (>150 mL)
• History of urinary retention
• Severe lower urinary tract symptoms (IPSS >19)

Exercise extreme caution in:

• Elderly men (>65 years) even without known BPH
• Patients on other medications affecting bladder function
• Those with diabetes, prior pelvic surgery, or neurological conditions affecting bladder control

If escitalopram is essential despite risk factors:

• Start at lowest dose (5 mg daily)
• Monitor PVR at 2 weeks and monthly for 3 months
• Instruct patient to report any change in urinary stream immediately
• Have low threshold for discontinuation if symptoms develop

The key clinical pearl: urinary retention from escitalopram is often overlooked because SSRIs are not typically suspected as causative agents 5. Maintain high clinical suspicion in elderly men developing new voiding difficulties after starting escitalopram.